Zobrazeno 1 - 10
of 4 236
pro vyhledávání: '"remitting multiple sclerosis"'
Publikováno v:
Romanian Journal of Laboratory Medicine, Vol 32, Iss 3, Pp 245-254 (2024)
Multiple sclerosis (MS) is a debilitating neurological disease characterized by inflammation, demyelination, and neurodegeneration in the central nervous system. Despite extensive research, the pathology of MS remains incompletely understood. Ocreliz
Externí odkaz:
https://doaj.org/article/5ca210c4947f4e94882b1ceb14d459a7
Autor:
Esther Ganelin‐Cohen, Chen Buxbaum, Noam Bosak, Shani Sobol, Adi Vaknin‐Dembinsky, Mark A Hellmann, Adi Wilf‐Yarkoni, Keren Regev, Elizaveta Pustovoyt, Alla Shifrin, Yair Wexler, Ayal Rozenberg
Publikováno v:
Brain and Behavior, Vol 14, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction Examining the safety of theBNT162b2 mRNA vaccine in multiple sclerosis (MS) patients remains inconclusive, particularly regarding the potential for disease exacerbations. This study aims to assess the effects of BNT162b2 COVID
Externí odkaz:
https://doaj.org/article/83f6312cb48b48198f138f5ff81dad63
Autor:
Giovanna Borriello, Clara Grazia Chisari, Davide Maimone, Massimiliano Mirabella, Damiano Paolicelli, Francesco Assogna, Sandro Caradonna, Francesco Patti
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
Patient-reported outcomes (PROs) are essential for understanding the effects of MS and its treatments on patients’ lives; they play an important role in multiple sclerosis (MS) research and practice. We present the protocol for an observational stu
Externí odkaz:
https://doaj.org/article/47763cf7864043f7a8c30a5aa3fb3f51
Autor:
Nasrin Abulhasanbeigi Gallehzan, Majid Khosravi, Khosro Jamebozorgi, Nazanin Mir, Habib Jalilian, Samira Soleimanpour, Saeed Hoseini, Aziz Rezapour, Abbas Eshraghi
Publikováno v:
Health Economics Review, Vol 14, Iss 1, Pp 1-37 (2024)
Abstract Background Multiple sclerosis (MS) is a chronic, autoimmune, and inflammatory disease. The economic burden of MS is substantial, and the high cost of Disease-modifying drugs (DMDs) prices are the main drivers of healthcare expenditures. We c
Externí odkaz:
https://doaj.org/article/96415d0a4a3b46258b80319c370323e8
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background This retrospective study examined the humanistic burden of fatigue in patients with relapsing-remitting multiple sclerosis (RRMS), compared with adults without MS, using data from the 2017 and 2019 US National Health and Wellness
Externí odkaz:
https://doaj.org/article/a171b8a054bd452eba61cf25a84c10a8
Autor:
Mark S. Freedman, Patricia K. Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn, Bianca Weinstock-Guttman, Silva Markovic-Plese, Andrew Galazka, Fernando Dangond, Julie Korich, Anthony T. Reder
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 283-322 (2024)
Abstract Multiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central nervous system. Relapsing–remitting MS (RRMS), the most common form of the disease, is characterized by transient neurological dysfunction with concurr
Externí odkaz:
https://doaj.org/article/8f4b63ea68774d85b40c2425f80dbef2
Autor:
Marios Lemonaris, Kleopas A. Kleopa
Publikováno v:
Case Reports in Neurology, Vol 16, Iss 1, Pp 48-54 (2024)
Introduction: Multiple sclerosis (MS) is an autoimmune neurodegenerative disease which can rarely co-exist with neurofibromatosis 1 (NF1), a neurocutaneous inherited disorder that predisposes to oncogenesis. Patients who suffer from both conditions c
Externí odkaz:
https://doaj.org/article/73a96ea2fc3d41629aad9d4b8f56db1f
Publikováno v:
AboutOpen, Vol 11, Iss 1 (2024)
Background: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS). Natalizumab patent protection has expired, a
Externí odkaz:
https://doaj.org/article/8ab74f99bf844d3593f954dfa63f83ef
Autor:
Massimo Filippi, Laura Ferrè, Chiara Zanetta, Caterina Rizzi, Gabriella Pessina, Francesco Assogna, Maria A. Rocca
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
Disease-modifying therapies (DMTs) for multiple sclerosis (MS) reduce relapse frequency, magnetic resonance imaging (MRI) activity, and slow disability progression. Numerous DMTs are approved for relapsing forms of MS although real-world data on pati
Externí odkaz:
https://doaj.org/article/ef54c05740f2416b8afe67eb74d099e0
Autor:
Ziemssen, Tjalf, Lang, Michael, Schmidt, Stephan, Albrecht, Holger, Klotz, Luisa, Haas, Judith, Lassek, Christoph, Lang, Stefan, Winkelmann, Veronika E., Ettle, Benjamin, Schulze‑Topphoff, Ulf
Objective: To evaluate the 5-year real-world benefit–risk profile of fingolimod in patients with relapsing–remitting MS (RRMS) in Germany. Methods: Post-Authorization Non-interventional German sAfety study of GilEnyA (PANGAEA) is a non-interventi
Externí odkaz:
https://tud.qucosa.de/id/qucosa%3A89149
https://tud.qucosa.de/api/qucosa%3A89149/attachment/ATT-0/
https://tud.qucosa.de/api/qucosa%3A89149/attachment/ATT-0/